(Q40100090)

17 September 2017

title

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding (English)

1 reference

17 September 2017

1 reference

Lianghua Bin

1

1 reference

17 September 2017

Jacqueline Thorburn

2

1 reference

17 September 2017

Lance R Thomas

3

1 reference

17 September 2017

Peter E Clark

4

1 reference

17 September 2017

Robin Humphreys

5

1 reference

17 September 2017

Andrew Thorburn

6

1 reference

17 September 2017

language of work or name

English

0 references

publication date

31 July 2007

1 reference

Journal of Biological Chemistry

17 September 2017

published in

1 reference

17 September 2017

volume

282

1 reference

17 September 2017

issue

38

1 reference

17 September 2017

page(s)

28189-28194

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Targeting death receptors in cancer with Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Death receptor-induced cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Inactivating mutations of KILLER/DR5 gene in gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Tissue distribution of the death ligand TRAIL and its receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704210200

21 January 2018

Identifiers

DOI

10.1074/JBC.M704210200

1 reference

17 September 2017

1 reference